BioCentury
ARTICLE | Emerging Company Profile

InterMune: Layer upon layer

May 17, 1999 7:00 AM UTC

Armed with a marketed product, InterMune Pharmaceuticals Inc. believes it can become profitable in the next four years by adding indications to its Actimmune gamma interferon. The product, initially developed by Genentech Inc., was approved in 1991 to treat chronic granulomatous disease (CGD) and the company plans to gain additional approvals to treat multiple-drug resistant strains of tuberculosis, fungal infections and osteopetrosis.

InterMune will use profits from Actimmune sales to develop its earlier-stage bacterial virulence regulation technology...